for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Concert Pharmaceuticals Inc

CNCE.OQ

現在値

9.99USD

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

5.36

 - 

13.09

∙ 約20分前の相場を表示しています。

適時開示

Concert Pharmaceuticals Releases Additional Data From Phase 2 Clinical Trial Of CTP-543 In Alopecia Areata

June 12 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS RELEASES ADDITIONAL DATA FROM PHASE 2 CLINICAL TRIAL OF CTP-543 IN ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CTP-543 EXPECTED TO ADVANCE INTO PHASE 3 EVALUATION IN Q4 OF 2020.CONCERT PHARMACEUTICALS INC - ANALYSES SHOW STATISTICALLY SIGNIFICANT DIFFERENCES FROM PLACEBO FOR 8 MG AND 12 MG TWICE-DAILY COHORTS.

Concert Pharmaceuticals Reports Q1 2020 Financial Results

April 30 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.Q1 LOSS PER SHARE $0.70.Q1 EARNINGS PER SHARE ESTIMATE $-0.78 -- REFINITIV IBES DATA.CONTINUING TO MOVE FORWARD DEVELOPMENT OF OUR TWO CLINICAL DRUG CANDIDATES.

Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.86

Feb 27 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.QTRLY TOTAL REVENUE $13,000 VERSUS $13,000.QTRLY LOSS PER SHARE $0.86.Q4 EARNINGS PER SHARE VIEW $-0.79, REVENUE VIEW $13330.00 -- REFINITIV IBES DATA.

Concert Pharmaceuticals Announces Pricing Of Public Offering

Jan 28 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING.CONCERT PHARMACEUTICALS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4.7 MILLION SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $9.92PER SHARE.

Concert Announces Notice Of Allowance For Patent Application Of CTP-543

Jan 22 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION RELATED TO CTP-543, LEAD CANDIDATE FOR TREATMENT OF ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CLAIMS COVER PHARMACEUTICAL COMPOSITIONS OF CTP-543 AND METHODS OF TREATING ALOPECIA AREATA WITH CTP-543.CONCERT PHARMACEUTICALS INC - NEW PATENT EXPECTED TO EXPIRE IN 2037.CONCERT PHARMACEUTICALS - EXPECTS TO ADVANCE CTP-543 INTO PHASE 3 EVALUATION FOR ALOPECIA AREATA IN 2020.

Concert Pharmaceuticals Successfully Completes Open Label Trial Of Ctp-543 In Patients With Alopecia Areata

Dec 19 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS SUCCESSFULLY COMPLETES OPEN LABEL TRIAL OF CTP-543 IN PATIENTS WITH ALOPECIA AREATA.CONCERT PHARMACEUTICALS - RESULTS IN 8 MG TWICE-DAILY ARM CONSISTENT WITH PREVIOUSLY-REPORTED 8 MG TWICE-DAILY RESULTS FROM PHASE 2 TRIAL OF CTP-543.CONCERT PHARMACEUTICALS - TREATMENT WAS GENERALLY WELL TOLERATED IN BOTH ARMS OF STUDY.CONCERT PHARMACEUTICALS - EXPECTS TO MEET WITH FDA AND INITIATE PHASE 3 TESTING FOR CTP-543 FOR TREATMENT OF ALOPECIA AREATA IN 2020.

Concert Pharmaceuticals Q3 Loss Per Share $0.72

Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.72.Q3 EARNINGS PER SHARE ESTIMATE $-0.83 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF SEPTEMBER 30, 2019 TOTALED $121.5 MILLION.CONCERT PHARMACEUTICALS- EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND CO THROUGH 2020 UNDER CURRENT OPERATING PLAN.

Concert Pharma Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial

Sept 3 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.CONCERT PHARMACEUTICALS INC - ADVANCEMENT INTO PHASE 3 EVALUATION PLANNED IN 2020.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.

Concert Pharmaceuticals Q2 Loss Per Share $0.78

Aug 1 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TOTALED $136.6 MILLION.CONCERT PHARMACEUTICALS - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND COMPANY INTO SECOND HALF OF 2020.

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment

June 12 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 1 STUDIES EVALUATING CTP-692 IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA IN Q4 OF 2019.CONCERT PHARMA - SAFETY ASSESSMENTS IN SINGLE- & MULTIPLE-ASCENDING DOSE TRIALS IN HEALTHY VOLUNTEERS SHOWED DRUG WAS WELL TOLERATED OVER DOSE RANGES TESTED.CONCERT PHARMACEUTICALS - STUDY SHOWED KEY BLOOD AND URINE MARKERS OF KIDNEY FUNCTION DID NOT INDICATE ANY SIGNS OF RENAL IMPAIRMENT.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up